Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis

• Main Authors: A. A. Kubanov (Author), A. L. Bakulev (Author), M. I. Gluzmin (Author), M. M. Kokhan (Author), L. S. Kruglova (Author), N. S. Rudneva (Author), O. Yu. Olisova (Author), E. V. Sokolovsky (Author), M. M. Khobeish (Author)
• Format: Book
• Published: State Scientific Center of Dermatovenereology and Cosmetology, 2019-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Tumor necrosis factor alpha (TNF-α) is one of the key inflammatory cytokines in the pathogenesis of psoriasis and psoriatic arthritis, and its inhibition with genetically engineered biological drugs ensures control of the main symptoms of these diseases. Certolizumab pegol is a PEGylated (linked to...